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he biological antagonism between Notch and Numb
controls the proliferative/differentiative balance in
development and homeostasis. Although altered
Notch signaling has been linked to human diseases, in-
cluding cancer, evidence for a substantial involvement of
Notch in human tumors has remained elusive. Here, we
show that Numb-mediated control on Notch signaling is
lost in 
 
 
 
50% of human mammary carcinomas, due to
speciﬁc Numb ubiquitination and proteasomal degradation.
Mechanistically, Numb operates as an oncosuppressor, as
its ectopic expression in Numb-negative, but not in Numb-
T
 
positive, tumor cells inhibits proliferation. Increased Notch
signaling is observed in Numb-negative tumors, but reverts
to basal levels after enforced expression of Numb. Con-
versely, Numb silencing increases Notch signaling in normal
breast cells and in Numb-positive breast tumors. Finally,
growth suppression of Numb-negative, but not Numb-
positive, breast tumors can be achieved by pharmacologi-
cal inhibition of Notch. Thus, the Numb/Notch biological
antagonism is relevant to the homeostasis of the normal
mammary parenchyma and its subversion contributes to
human mammary carcinogenesis.
 
Introduction
 
Notch is a plasma membrane receptor involved in the control of
cell fate specification and in the maintenance of the proliferative/
differentiative balance in many cell lineages (Artavanis-Tsakonas
et al., 1999; Mumm and Kopan, 2000), and alterations in Notch
signaling have been implicated in tumorigenesis (Robbins et
al., 1992; Gallahan et al., 1996; Capobianco et al., 1997).
However, with the exception of a rare translocation in T cell
malignancies (Ellisen et al., 1991), no genetic lesion of the
 
Notch
 
 locus has been described in human tumors. Increased
Notch signaling profoundly impairs normal mammary gland
morphogenesis in mice, promoting the rapid development of
poorly differentiated adenocarcinomas (Jhappan et al., 1992;
Gallahan et al., 1996). This finding raises the possibility that
subversion of Notch signaling might play a role in human
breast tumors; yet little direct evidence for such an involve-
ment has been provided so far (Weijzen et al., 2002). Thus, one
major question is whether and how 
 
Notch
 
 is altered in human
breast tumors, and how deregulation of its signaling might
contribute to the neoplastic phenotype.
During asymmetric cell division in embryogenesis, the
activity of Notch is biologically antagonized by the cell fate
determinant Numb (Rhyu et al., 1994; Guo et al., 1996). However,
Numb is also expressed in many adult mammalian cells (Santolini
et al., 2000), where it does not display asymmetrical partitioning
at mitosis, suggesting additional functions. We reasoned that
if the Numb/Notch antagonism is relevant to control of the
proliferative/differentiative balance in the normal mammary
parenchyma, then subversion of the Numb-mediated regulation
of Notch might play a causative role in naturally occurring breast
cancers. The present work was undertaken to test this possibility.
 
Results and discussion
 
A preliminary survey of the expression of Numb in normal and
tumor tissues of different origins (unpublished data) revealed
frequent alterations in breast tumors. Thus, we characterized
321 consecutive breast cancers by immunohistochemistry
(Table S1, available at http://www.jcb.org/cgi/content/full/
jcb.200406140/DC1). The normal breast parenchyma invari-
ably showed intense and homogeneous Numb staining (Fig. 1
A). Conversely, tumors displayed marked heterogeneity and in
many cases complete absence of Numb immunoreactivity,
which allowed their classification into three classes (Fig. 1 A).
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Class-1 (38.3% of the cases) tumors showed Numb staining in
 
 
 
10% of the neoplastic cells. Within this category, in fact,
more than 50% of class-1 tumors displayed no detectable
Numb immunoreactivity (type-0 tumors), whereas class-2 and
-3 tumors (16.8% and 44.9% of investigated cases, respectively)
showed Numb immunoreactivity in 10–50% and 
 
 
 
50% of the
tumor cells, respectively. Thus, more than one half of all breast
tumors (classes 1 and 2 combined) had reduced levels of
Numb. Remarkably, a strong inverse correlation was found be-
tween Numb expression levels and tumor grade (P 
 
  
 
0.001)
and Ki67 labeling index (P 
 
  
 
0.001), which are known indica-
tors of aggressive disease (Fig. 1 B and Table S1).
We analyzed the presence of 
 
Numb
 
 transcripts in human
mammary tumors by in situ hybridization. Five class-3 tumors
and 14 class-1(type-0) tumors were analyzed. All of the class-3
tumors (and normal glands surrounding the tumors) displayed
readily detectable levels of 
 
Numb
 
 transcripts (Fig. 1 C). Interest-
ingly, 12 of 14 class-1(type-0) tumors displayed levels of 
 
Numb
 
mRNA expression comparable to those detected in normal tis-
sues and class-3 tumors (Fig. 1 C). In addition, we could not de-
tect any genetic alteration affecting the 
 
Numb
 
 locus by analysis of
loss of heterozygosity (LOH) or by direct sequencing of 
 
Numb
 
cDNAs prepared from several Numb-negative tumors (Fig. S1 A,
available at http://www.jcb.org/cgi/content/full/jcb.200406140/
DC1). Thus, genetic alterations at the 
 
Numb
 
 locus are unlikely to
account for the absence of Numb protein in these tumors.
To gain insight into the molecular mechanisms responsi-
ble for loss of Numb expression, we established primary cul-
tures from class-1(type-0) and class-3 mammary tumors and
from normal breast tissues from the same patients, and ana-
lyzed them within the first two passages in vitro (Fig. S1 B).
All primary cultures from normal breast and tumor cultures
from class-3 patients displayed high levels of Numb expres-
sion, which were only marginally affected by treatment with
the proteasome inhibitor MG132 (Fig. 2, A and B). In contrast,
primary cultures from class-1(type-0) patients displayed little,
if any, basal Numb expression. However, Numb levels were re-
stored to high levels by treatment with MG132 (Fig. 2, A and
B). Reduction of Numb levels in class-1 tumors did not appear
to be the consequence of a generally increased proteasomal ac-
tivity, as the basal levels of other cellular proteins also regu-
lated by proteasomal degradation, such as 
 
 
 
-catenin, were not
affected under the same experimental conditions (Fig. 2 C).
It has been proposed that ubiquitination followed by pro-
teasomal degradation represents a major mechanism for cellu-
lar regulation of Numb (Juven-Gershon et al., 1998; Susini et
al., 2001; Nie et al., 2002); thus, we investigated the pattern of
Numb ubiquitination in tumor cells. As shown in Fig. 2 D, the
restoration of Numb levels in class-1 tumor cells by treatment
with MG-132 for 6 h was accompanied by a dramatic increase
in Numb polyubiquitination, whereas no effect of MG132 on
Numb polyubiquitination was evident in class-3 tumors. To-
gether, these results provide compelling evidence that en-
hanced ubiquitination and consequent increased proteasome-
mediated degradation accounts for the loss of Numb expression
in a substantial proportion of mammary tumors.
The possibility that enhanced degradation of Numb is
causally involved in the progression of breast cells toward ma-
lignancy prompted us to test the consequences of restoration of
Numb levels in primary tumor cells. Retrovirally mediated
transient overexpression of a fusion Numb-GFP protein in pri-
mary cells from class-1 tumors resulted in a clear reduction in
colony-forming ability (Fig. 3 A). Conversely, class-3 tumor
cells were unaffected, despite similar levels of Numb-GFP ex-
pression upon transient infection (Fig. 3 B).
Figure 1. Numb expression in human mammary tumors. (A) The typical
immunoreactivity for Numb in normal breast (normal) showed intense staining
in the vast majority of ductal (luminal) and lobular epithelial cells, with a
prominent membranous staining pattern. Examples are shown of typical
class-1(type-0), class-2, and class-3 tumors. Arrowheads point to normal
glands within the context of the tumors. (B) Correlation between Numb
status and clinical-pathological features. Details and explanations are
in Table S1, available at http://www.jcb.org/cgi/content/full/jcb.
200406140/DC1. Ki67, proliferative index; LN, lymph nodes. P value
was obtained using the Mantel-Haenszel Chi square statistics. (C) In situ
hybridization with an antisense probe for Numb mRNA was performed on
paraffin sections. Control hybridizations with a corresponding sense probe
gave no signal (not depicted). Examples of matching bright fields (top) and
dark fields (bottom) of class-1 (left) and class-3 (right) tumors are shown.
Numb transcripts appear as bright spots in the dark fields (bottom). 
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Overall, the sum of our results points to a direct link be-
tween increased degradation of Numb and uncontrolled cell pro-
liferation in a subset of human mammary gland tumors. The well
established biological antagonism between Numb and Notch al-
lowed us to test the hypothesis that aberrant regulation of Notch
signaling in human breast tumors is due to a deficiency of Numb
activity. Lack of Numb in tumor cells would be expected to be
reflected in Notch activity. Notch is activated through a series of
proteolytic cleavages ultimately leading to the release of its solu-
ble intracellular domain (ICD) from the plasma membrane
(Schroeter et al., 1998; Struhl and Adachi, 2000). The ICD is
translocated to the nucleus, where it regulates gene transcription
by interacting with the DNA binding-protein RBP-
 
J
 
k/CBF-1
(Jarriault et al., 1998). The biochemical mechanisms through
which Numb antagonizes Notch are not yet clear; however, one
leading hypothesis is that direct binding of Numb to Notch pre-
vents nuclear translocation and hence transcriptional activity of
the ICD (Frise et al., 1996; Guo et al., 1996; Zhong et al., 1996).
Therefore, we used primary tumor cells to monitor the
subcellular distribution and activation state of Notch. In class-
1(type-0), Notch immunostaining appeared lower than in class-3
tumors or normal cells (Fig. 4 A). We reasoned that this find-
ing might be consistent with increased processing of Notch at
the plasma membrane followed by increased nuclear transloca-
tion of the ICD into the nucleus, whereby it is promptly de-
graded by the nuclear proteasomal machinery. Indeed, even
brief (1 h) MG132 treatment revealed nuclear accumulation of
Notch (ICD) in all class-1(type-0) cells, but not in class-3
tumors or normal counterparts (Fig. 4 A). We measured Notch
function by following luciferase activity driven from a Notch-
dependent CBF1-responsive reporter (6x-RBP-
 
J
 
k-luc) trans-
fected into primary cells. Luciferase activity was similar among
class-3 and normal cultures but clearly increased in all class-1
cultures (Fig. 4 B). Furthermore, by using quantitative RT-PCR,
we found that endogenous expression of the 
 
HES-1
 
 mRNA, a
known target gene for Notch transcriptional activity (Sasai et
al., 1992; Jarriault et al., 1998), was significantly higher in
class-1 tumor cells than in class-3 cells or their normal counter-
parts (Fig. 4 C).
These results prompted us to assess directly a possible
functional link between Numb levels and Notch activity in tu-
mor cells. RNAi-mediated silencing of Numb in primary nor-
mal breast cells resulted in a significant increase in 
 
HES-1
 
mRNA transcripts in comparison to cells transfected with a
Figure 2. Loss of Numb expression in tumors
is due to enhanced ubiquitination and protea-
somal degradation. (A) Matched normal (top)
and tumor (bottom) primary cells from class-1
(right) and class-3 (left) patients were treated
with MG132 ( ) for 12 h or mock treated ( )
and stained with anti-Numb. (B) Total cellular
lysates from the same cells as in A were immuno-
blotted with anti-Numb (top). Molecular mass
is indicated in kilodaltons on the right. Typi-
cally, two Numb-specific bands (each probably
corresponding to a tightly spaced doublet) are
detected in human mammary cells. Equal
loading was checked with anti-actin (bottom).
(C) Primary tumor mammary cells were either
mock treated ( ) or exposed to MG132 ( )
for 12 h. Lysates were immunoblotted (WB)
with the indicated antibodies. (D) Tumor mam-
mary cells from class-1 and class-3 patients
were either mock treated ( ) or exposed to
MG132 ( ) for 6 h. Lysates were immuno-
precipitated (IP) with a monoclonal anti-Numb
antibody and immunoblotted (WB) with the
indicated antibodies. Molecular mass is indi-
cated in kilodaltons on the right. Results in all
panels are representative of three independent
experiments. In addition, similar results were
obtained with primary cultures from three
class-1(type-0) and three class-3 patients (not
depicted). 
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control siRNA (Fig. 5 A). As expected, a similar increase in
Notch-dependent transcriptional activity was observed in class-3
tumor cells, but not in class-1 tumor cells (Fig. 5 A). Accord-
ingly, retrovirally mediated overexpression of Numb caused a
significant decrease in basal Notch activity in class-1, but not
in class-3, tumor cells (Fig. 5 B) or in normal cells from the
same patients (not depicted). As overexpression of Numb in
class-1 tumor cells also caused a significant growth-suppres-
sion effect (Fig. 3), we directly tested the possibility that dereg-
ulated Notch activity arising from loss of Numb might be re-
sponsible for uncontrolled cell proliferation in class-1 tumors.
We took advantage of the small molecule peptidomimetic pre-
senilin inhibitor DFP-AA, which blocks Notch signaling and
effectively suppresses the growth of Notch1-transformed lym-
phoid cell lines in vitro (Weng et al., 2003). DFP-AA treatment
of class-1 tumor cells was sufficient to cause a dramatic sup-
pression of their growth potential (Fig. 5 C), which was accom-
panied by a marked decrease in Notch activity, as assessed by
 
HES-1
 
 mRNA levels (Fig. 5 D). In contrast, no significant ef-
fect was observed in class-3 tumor cells (Fig. 5, C and D).
Using breast tumor specimens and primary cells derived
from them, this work has established that deregulation of Numb-
mediated control on Notch signaling is a frequent occurrence in
human breast cancer. Indeed, loss of Numb expression leads to
activation of Notch, which in turn is responsible for increased
proliferation of tumor cells. Accordingly, restoration of physio-
logical Numb levels or inhibition of Notch activity attenuated the
hyperproliferative state of Numb-negative tumors. Importantly,
Numb-positive tumors were unaffected by these manipulations.
Thus, 
 
Numb
 
 and 
 
Notch
 
 fulfill the operational definitions of onco-
suppressor and oncogene, respectively, in human breast cancers.
Loss of Numb expression in breast cancers is due to its in-
creased ubiquitination and resultant proteasomal degradation,
raising the issue of the genetic lesion responsible for excessive
Numb ubiquitination. Consistent with findings that Numb levels
are regulated by E3-ligases, such as LNX, Siah-1, and Mdm2
(Juven-Gershon et al., 1998; Susini et al., 2001; Nie et al., 2002),
an obvious possibility is that there are increased levels or activ-
ity of an E3-type ubiquitin ligase. In this context, it would be in-
teresting to test in our ex vivo model the effects of a new class of
Figure 3. Re-expression of Numb selectively
suppresses growth in Numb-negative tumors.
(A) Primary tumor cells from class-1(type-0)
(left) and class-3 (right) patients were trans-
duced with retroviruses encoding GFP or
Numb-GFP. After 3 wk, plates were fixed and
stained (bottom). The histograms show the av-
erage number of colonies (colony-forming
units   SD) from three plates. Similar results
were obtained with primary cultures from
three independent class-1(type-0) and three
independent class-3 patients (not depicted).
(B) The expression of GFP and Numb-GFP, as
detected by epifluorescence (top) or immuno-
blot (bottom), upon transient retroviral delivery
is shown to demonstrate equal efficiency of
infection/expression. 
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cytotoxic agents with antiproteasomal activity, exemplified by
the PS-341 compound, currently under clinical evaluation for
advanced cancers (Adams et al., 1999). Alternatively, increased
Numb phosphorylation might cause its ubiquitination and degra-
dation, as a strong correlation between these two posttransla-
tional modifications has been shown for other proteins (Pickart,
2001). Of note, in 
 
Drosophila melanogaster
 
, a serine/threonine
kinase, NAK, physically interacts with Numb and causes loss-
of-Numb-function phenotypes upon overexpression (Chien et
al., 1998). Under this scenario, the primary lesion would affect a
serine/threonine kinase (Numb is serine/threonine phosphory-
lated), rather than an E3-ligase. Whatever the case, restoration of
Numb function might in principle be obtained by pharmacologi-
cal inhibition of the enzyme(s) responsible for its degradation: a
therapeutic possibility with obvious appeal.
 
Materials and methods
 
Tissue samples and primary cells
 
Mammary tissue specimens were obtained from breast cancer patients un-
dergoing surgery. Pure populations of epithelial cells were obtained as de-
scribed previously (Hammond et al., 1984; Speirs et al., 1998). The epithe-
lial origin of the cultures was confirmed by immunofluorescence with an anti-
Pan cytokeratin antibody (Sigma-Aldrich). Second-passage cells, practically
free of nonepithelial cells, were used for all described experiments (Fig. S1
B). MG132 was used at 10 
 
 
 
M. 1 
 
 
 
M DFP-AA (compound E; Calbiochem)
was added in fresh medium every 24 h for 10 d. Mock-treated controls were
exposed to equivalent concentrations of carrier (0.05% dimethyl sulfoxide).
 
Expression vectors and biological assays
 
A Numb-GFP expression vector was obtained by recombinant PCR and
subcloning in a retroviral (Pinco) vector, followed by sequence verifica-
tion. Primary cells (50,000 per well) were infected in 6-well plates with su-
pernatants from 
 
 
 
NX (Phoenix cells) transfected with Pinco-Numb-GFP or
with Pinco-GFP every 3 d for 3 wk.
A luciferase reporter plasmid (6x-RBP-
 
J
 
k-luc, provided by U. Len-
dahl, Karolinska Institute, Stockholm, Sweden) containing six copies of the
CBF1 binding consensus sequence was used to evaluate Notch signaling.
Primary mammary cells were transfected in 6-well plates with 800 ng of
6x-RBP-
 
J
 
k-luc and 200 ng of CMV-
 
 
 
-galactosidase expression plasmids.
Luciferase activity was evaluated 48 h after transfection and normalized
for transfection efficiency by 
 
 
 
-galactosidase expression.
 
Protein studies and siRNA
 
An affinity-purified anti-Numb peptide antibody was used for immuno-
blotting, immunofluorescence, and immunocytochemistry (Santolini et al.,
2000), according to standard procedures.
To assess its ubiquitination state in tumors in vivo, Numb was immu-
noprecipitated with a mouse mAb raised against exon-10 of human
Numb and not cross-reactive with the 
 
Numb
 
-related gene Numbl, fol-
lowed by immunoblot with the anti-Ub antibody FK1 (Affiniti Research
Product). Other antibodies used were as follows: anti-Notch1 (c-20; Santa
Cruz Biotechnology. Inc.), HRP-conjugated secondary antibodies (Amer-
sham Biosciences), and Cy3- and FITC-conjugated secondary antibodies
(Jackson ImmunoResearch Laboratories). For siRNA experiments, delivery
of siRNA oligos was achieved using Oligofectamine. The targeted se-
quences were as follows: Numb siRNA, CAGCCACUGAACAAGCAGA;
scrambled siRNA, AGACGAACAAGUCACCGAC.
 
In situ hybridization
 
Numb
 
 expression was assessed by in situ hybridization using 
 
35
 
S-UTP–labeled
sense and antisense riboprobes. After overnight hybridization at 50
 
 
 
C, tissue
sections were washed in 50% formamide, 2
 
 
 
 SSC, and 20 mM 2-mercapto-
ethanol at 60
 
 
 
C and coated with Kodak NTB-2 liquid emulsion to reveal ra-
diolabeling. Sequences of the probes are available upon request.
 
Quantitative RT-PCR
 
Quantitative RT-PCR analysis was performed on the Prism 7700 Sequence
Detection System (Applied Biosystems). Each cDNA sample was tested
in triplicate. For quantification of gene expression changes, the 
 
  
 
Ct
Figure 4. Increased Notch signaling in Numb-negative tumors. (A) Primary
tumor cells from class-1(type-0) (top) and class-3 (bottom) patients were
treated with MG132 ( ) or mock treated ( ) for 1 h and stained with
anti-Notch. Note the lower basal levels of Notch expression in class-1
MG132-untreated cells and the presence of nuclear Notch in the same
class upon MG132 treatment. (B) CBF1-responsive reporter gene activity
was evaluated in normal and tumor cells from class-1(type-0) and class-3
patients. (C) HES-1 mRNA expression in total RNAs from normal and tumor
cells from class-1(type-0) and class-3 patients. In B and C, the mean fold
induction (  SD) from two independent experiments performed in tripli-
cate is shown. In all panels, results are representative of those obtained
with primary cultures from three class-1(type-0) and three class-3 patients
(not depicted). 
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method was used to calculate relative fold changes normalized against
the 
 
glyceraldehyde 3-phosphate dehydrogenase
 
 gene, as described in the
manufacturer’s protocol (Applied Biosystems).
 
Microscopic analysis and image acquisition
 
Immunofluorescence specimens, mounted in 90% glycerol with paraphe-
nylenediamine as an antibleaching agent, were examined at RT using an
epifluorescence microscope (model AX70 Provis; Olympus) with a 60
 
 
 
/
1.4 NA PlanAPO oil immersion lens or a 40
 
 
 
/0.85 UplanAPO objective.
Images were obtained with a digital camera (model C5985 B/W CCD;
Hamamatsu) using an acquisition software (Hamamatsu C5985 Plugin for
Adobe Photoshop). Tissue sections were observed with a DMLB micro-
scope (Leica) equipped with a digital color camera (model DXC-950P
3CCD; Sony; TRIBVN ICS software for Windows), using a 10
 
 
 
/0.40 NA
or a 20
 
 
 
/0.70 NA plan-APO objective. Digital images were computer
processed using Adobe Photoshop 7.
 
Online supplemental material
 
Fig. S1 describes in detail procedures used for LOH analysis (A) and char-
acterization of primary cultures (B). The clinical-pathological features of
patients and details of immunohistochemical analysis are described in Ta-
ble S1. Online supplemental material is available at http://www.jcb.org/
cgi/content/full/jcb.200406140/DC1.
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